ALNYLAM PHARMACEUTICALS, INC. Annual Interest Expense in USD from 2018 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of the cost of borrowed funds accounted for as interest expense.
Summary
Alnylam Pharmaceuticals, Inc. quarterly/annual Interest Expense history and growth rate from 2018 to 2023.
  • Alnylam Pharmaceuticals, Inc. Interest Expense for the quarter ending March 31, 2024 was $35.3M, a 21.8% increase year-over-year.
  • Alnylam Pharmaceuticals, Inc. Interest Expense for the twelve months ending March 31, 2024 was $128M, a 10.6% decline year-over-year.
  • Alnylam Pharmaceuticals, Inc. annual Interest Expense for 2023 was $121M, a 22.3% decline from 2022.
  • Alnylam Pharmaceuticals, Inc. annual Interest Expense for 2022 was $156M, a 9.05% increase from 2021.
  • Alnylam Pharmaceuticals, Inc. annual Interest Expense for 2021 was $143M, a 69.3% increase from 2020.
Interest Expense, Trailing 12 Months (USD)
Interest Expense, Annual (USD)
Interest Expense, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $121M -$34.7M -22.3% Jan 1, 2023 Dec 31, 2023 10-K 2024-02-15
2022 $156M +$12.9M +9.05% Jan 1, 2022 Dec 31, 2022 10-K 2024-02-15
2021 $143M +$58.5M +69.3% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-15
2020 $84.5M +$84.5M Jan 1, 2020 Dec 31, 2020 10-K 2023-02-23
2019 $0 $0 Jan 1, 2019 Dec 31, 2019 10-K 2022-02-10
2018 $0 Jan 1, 2018 Dec 31, 2018 10-K 2021-02-11
* An asterisk sign (*) next to the value indicates that the value is likely invalid.